A61P 27/02
Ophthalmic agents
A61P27/02 (Ophthalmic agents) appears on 22,392 US grants and 34,769 published applications in this corpus.
Search patents in A61P- Granted patents
- 22,392
- Published applications
- 34,769
- Assignees
- 7,304
- Inventors
- 44,946
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 2 | 0 |
| 1978 | 12 | 0 |
| 1979 | 9 | 0 |
| 1980 | 14 | 0 |
| 1981 | 6 | 0 |
| 1982 | 8 | 0 |
| 1983 | 8 | 0 |
| 1984 | 20 | 0 |
| 1985 | 20 | 0 |
| 1986 | 15 | 0 |
| 1987 | 17 | 0 |
| 1988 | 37 | 0 |
| 1989 | 42 | 0 |
| 1990 | 59 | 0 |
| 1991 | 64 | 0 |
| 1992 | 68 | 0 |
| 1993 | 81 | 0 |
| 1994 | 89 | 0 |
| 1995 | 127 | 0 |
| 1996 | 125 | 0 |
| 1997 | 166 | 0 |
| 1998 | 196 | 0 |
| 1999 | 236 | 0 |
| 2000 | 265 | 0 |
| 2001 | 349 | 92 |
| 2002 | 448 | 582 |
| 2003 | 413 | 997 |
| 2004 | 356 | 1235 |
| 2005 | 354 | 1287 |
| 2006 | 497 | 1402 |
| 2007 | 516 | 1407 |
| 2008 | 594 | 1768 |
| 2009 | 696 | 2052 |
| 2010 | 1064 | 2255 |
| 2011 | 1121 | 2154 |
| 2012 | 1356 | 2116 |
| 2013 | 1575 | 1738 |
| 2014 | 1552 | 1749 |
| 2015 | 1353 | 1548 |
| 2016 | 1172 | 1629 |
| 2017 | 1150 | 1452 |
| 2018 | 1088 | 1400 |
| 2019 | 969 | 1296 |
| 2020 | 911 | 1222 |
| 2021 | 791 | 1155 |
| 2022 | 613 | 1027 |
| 2023 | 511 | 946 |
| 2024 | 506 | 935 |
| 2025 | 457 | 752 |
| 2026 | 293 | 573 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Polysaccharide encapsulated oxygen nanobubbles6 Oct 2026US 12,751,927 B2The Board of Trustees of the University of Illinois
- Topical ocular delivery of cromakalim6 Oct 2026US 12,751,939 B2Mayo Foundtation for Medical Education and Research
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Compositions and methods for treating age-related macular degeneration29 Sep 2026US 12,746,246 B2Tufts Medical Center, Inc.
- Blood-brain barrier permeable heteroduplex nucleic acid29 Sep 2026US 12,746,253 B2National University Corporation Tokyo Medical and Dental University
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306431 A1Geneiii Biotech Company Ltd.
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306457 A1Geneiii Biotech Company Ltd.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Novel glycan compounds for age-related macular degeneration8 Oct 2026US 2026/0306530 A1The Regents of the University of California
- Retinal pigment epithelium cell therapy8 Oct 2026US 2026/0306548 A1The Regents of the University of California
Most cited
By later US patents
- Drug delivery devices, kits and methods therefor1,366US 8,521,273 B22013
- Controlled-release biocompatible ocular drug delivery implant devices and methods780US 6,331,313 B1Oculex Pharmaceticals, Inc. · 2001
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014